allion logo
Allion Healthcare, Inc.
1660 Walt Whitman Road, Suite 105
Melville, NY 11747
Tel: (631) 547-6520

Allion Healthcare Reports Record First quarter 2009 Revenues of $97 million and Fully Diluted EPS of $0.13 and Increases Annual EPS Guidance to $0.50 - $0.52


•  
Fully Diluted EPS Guidance increased to $0.50 to $ 0.52 per share
•  
Net sales increased 48% to $96.6 million from $65.3 million
•  
Net income increased to $3.5 million compared to a net loss of $1.3 million
•  
Earnings per diluted share increased to $0.13 compared to a net loss of $0.08
•  
Specialty HIV net sales increased 9% to $71.0 million
•  
Specialty Infusion net sales increased 6% sequentially to $25.6 million over the fourth quarter of 2008

MELVILLE, NY – May 7, 2009 –
Allion Healthcare (NASDAQ: ALLI) today announced financial results for the first quarter ended March 31, 2009.  Results for the period include the Company’s expansion into the Specialty Infusion market as a result of the April 4, 2008 acquisition of Biomed America, Inc. (“Biomed”). Allion Healthcare now operates its business in two segments: Specialty HIV, which is the Company’s legacy specialty pharmacy and disease management business focused on HIV/AIDS patients, and Specialty Infusion, which is the Company’s recently acquired Biomed business specializing in biopharmaceutical medications and services for chronically ill patients.

Summary of Results
 
Consolidated net sales increased 48% to $97 million for the quarter ended March 31, 2009 when compared to the first quarter of 2008.  Both business segments grew organically with Specialty HIV up 9% to $71 million when compared to the first quarter of 2008 and Specialty Infusion up sequentially 6% over the fourth quarter of 2008.

Adjusted EBITDA more than tripled to $8.8 million in the first quarter of 2009, compared to $2.7 million during the first quarter of 2008. The increase in Adjusted EBITDA primarily resulted from the $5.8 million contribution from the Biomed acquisition. An explanation and reconciliation of Net income under GAAP to EBITDA and Adjusted EBITDA is provided below.

Net income for the first quarter of 2009 increased to $3.5 million, compared to a net loss of $1.3 million for the same period in 2008. Earnings per diluted share for the first quarter of 2009 were $0.13, compared to loss per diluted share of $0.08 for the first quarter of 2008.

Fully diluted shares outstanding for the three-month period ended March 31, 2009 include 1,719,000 contingently issuable shares related to the component of the Biomed earn out estimated to be settled in stock.  Based on the Specialty Infusion operating results through March 31, 2009, the Company included an estimate of its total obligations under the Biomed earn out and recorded a long-term liability and an addition to goodwill of $50.0 million.  The final amount paid, which is expected to be made some time in the third quarter of 2009, will be made in a combination of the Company’s common stock, subordinated debt and/or cash.


The following information was filed by Allion Healthcare Inc on Thursday, May 7, 2009 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Allion Healthcare Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Allion Healthcare Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account